Catalyst Pharmaceutical Partners, a pharmaceutical company developing prescription drugs to treat addiction, priced 3.35 million shares at $6. This came after the company lowered the proposed price to $6 from its originally proposed $11-$13 range on Tuesday. The stock is expected to begin trading on the NASDAQ on Wednesday under the ticker CPRX. First Albany Capital managed the deal.
